Q1 2026 Xvivo Perfusion AB Earnings Call Transcript
Key Points
- Xvivo Perfusion AB (XVIPF) reported a 23% organic top-line growth in Q1 2026, with a positive cash flow for the second consecutive quarter.
- The thoracic and abdominal segments are experiencing rapid growth in both North America and Europe.
- Strong kidney sales were reported, fueled by the Canadian launch and growing interest in the United States.
- The OPO hub pilot was successful, contributing to increased line sales and ahead of internal plans.
- The company is seeing high interest from trial centers for its heart technology, with plans to extend the CAP program.
- Gross margins in the abdominal and services segments were softer compared to thoracic margins.
- The organ recovery business showed negative growth, with a decrease in gross margin due to lower case volumes.
- There are ongoing regulatory challenges, with the company awaiting feedback for C-marking in Europe.
- The CAP program for heart technology is limited by FDA approvals, affecting the number of patients that can be treated.
- The abdominal gross margin was impacted by a larger portion of sales to lower-priced markets, such as Asia and Eastern Europe.
Welcome to Xvivo Perfusion Q1 Report for 2026. (Operator Instructions)
Now I will hand the conference over to CEO Christopher Rosenblad and CFO Kristoffer Nordström. Please go ahead.
Thank you so much. Good morning and good afternoon, everyone, and welcome to Ex Vivo's earning call for the first quarter of 2026.
We can go to slide number two and just today's presenter are me, Christopher Rosenblatt, calling in from the 2026 ISHIT conference in Toronto, Canada, and Christopher Nordstrom, CFO, calling in from Philadelphia in the United States. And with that, we can go to slide number three, Financial at a Glance. So, we see that the first quarter of this year showed a 23% organic top-line growth. This is equivalent to an 18% organic top-line growth if we adjust for the US cap trial revenue compared to the same quarter last year.
EBITDA was kept at a healthy level, resulting in a positive cash flow for the second consecutive quarter. The CFO, Christopher Nordstrom,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
